We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





Diasys Launches New SARS-CoV-2 UTAB FS Universally Applicable Total Antibody Test

By LabMedica International staff writers
Posted on 02 Mar 2021
DiaSys Diagnostic Systems GmbH (Holzheim, Germany) has launched a new immunoturbidimetric test for the quantitative determination of total antibodies in COVID-19.

The universally applicable total antibody test, called SARS-CoV-2 UTAB FS (UTAB = Universal Total AntiBody), allows to detect whether a person has already been infected with SARS CoV-2 and may have developed immunity to the corona virus. More...
The test detects antibodies of the early immune response (IgM and IgA antibodies) as well as antibodies that evoke a more long-lasting specific immune response in blood (antibody class IgG). The SARS-CoV-2 UTAB FS test for clinical diagnostic laboratories provides reliable and indicative results for patient management within only 10 minutes. The test requires no special equipment and allows comparable results on nearly all clinical chemistry analyzers available worldwide.

It is scientifically proven that the virus attaches to the host cell via a special binding site in the spike 1 envelope protein, the so-called receptor binding domain, or RBD for short, and then infects the host cell. Antibodies against this RBD are able to suppress the attachment of the virus to the host cell and thus its infection and are consequently called neutralizing antibodies. Due to the importance of these antibodies, DiaSys has selected the RBD as the target antigen for the assay to determine total antibodies in COVID-19.

Quantitative assessment of antibodies against the RBD domain of the spike protein, so-called anti-RBD SARS-CoV-2 antibodies, is becoming increasingly important. It provides information on the actual spread of infection in the population and enables characterization of a vaccine-induced immune response. It allows to define the initial antibody status, captures the change in antibody levels induced by a vaccine, and permits to judge the efficacy of a vaccine and to determine required vaccination intervals.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.